Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3604
Title: | Management of children and adolescents with bronchiectasis: Summary of the ers clinical practice guideline | Authors: | Kantar, A. Fortescue, R. Powell, Z. Chang, Anne Grimwood, K. Boyd, J. |
Issue Date: | 2021 | Source: | 17, (3), 2021 | Journal: | Breathe | Abstract: | Bronchiectasis, characterised by chronic wet/productive cough with recurrent respiratory exacerbations and abnormal bronchial dilatation on computed tomography scans, remains an increasingly recognised but often neglected chronic pulmonary disorder in children and adolescents. An early diagnosis combined with optimal management offers the prospect, at least in some patients, of curing a condition previously considered irreversible. However, unlike in adults, until now no international paediatric guidelines existed. The recently published European Respiratory Society clinical practice guidelines for the management of children and adolescents with bronchiectasis attempts to address this clinical information gap. The guidelines were formulated by panel members comprised of experts from several relevant health fields, the European Lung Foundation and parents of children with bronchiectasis. Systematic reviews and the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach guided the nature and strength of recommendations. The recommendations are grouped into clinically relevant topics: diagnosis, evaluating for underlying causes, defining exacerbations, management, systematic care, monitoring, reversibility and prevention. The guidelines seek to achieve: 1) optimal lung growth, 2) preserved lung function, 3) enhanced quality of life, 4) minimal exacerbations, 5) few or no complications, and 6) if possible, reversal of lung injury for each child/adolescent with bronchiectasis. This review presents example cases that highlight the recommendations of the clinical practice guidelines.L20144972702021-11-18 | DOI: | 10.1183/20734735.0105-2021 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2014497270&from=exporthttp://dx.doi.org/10.1183/20734735.0105-2021 | | Keywords: | economics;female;fever;forced expiratory volume;GRADE approach;human;human experiment;Human respiratory syncytial virus;human tissue;immune deficiency;lung clearance;lung disease;lung function;lung function test;male;physiotherapist;practice guideline;quality of life;recurrent disease;sputum culture;surgical technique;tuberculosis;review;fluoroscopy systemantibiotic agent;azithromycin;ceftriaxone;airway obstruction;asthma;biosurveillance;bronchiectasis;bronchodilatation;case report;child;chronic obstructive lung disease;clinical article;computer assisted tomography;coughing;cross infection;cystic fibrosis;disease burden;dyspnea | Type: | Article |
Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.